<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46981">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494609</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-120-NRM</org_study_id>
    <secondary_id>LX4211.120</secondary_id>
    <nct_id>NCT02494609</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive DDI Study</brief_title>
  <official_title>A Two-way Study to Evaluate the Potential Pharmacokinetic Interactions Between Sotagliflozin (LX4211) and Ortho-CyclenÂ®, an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol, in Healthy Premenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Two-way Study to Evaluate the Potential Pharmacokinetic Interactions Between Sotagliflozin
      (LX4211) and an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol, in Healthy
      Premenopausal Women.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of sotaglifozin to evaluate protocol specified PK parameters</measure>
    <time_frame>Day 6 to Day 8, Day 55 to Day 57, Day 62 to Day 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of norgestimate/ethinyl estradiol to evaluate protocol specified PK parameters</measure>
    <time_frame>Day 55 to Day 57, Day 62 to Day 64</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>Day 1 to Day 70</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily dosing for 7 days, followed by 7-day washout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily dosing for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sotagliflozin</intervention_name>
    <description>400 mg sotagliflozin</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive</intervention_name>
    <description>0.25 mg norgestimate/0.035 mg ethinyl estradiol</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral contraceptive + sotagliflozin</intervention_name>
    <description>0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal females with a body mass index (BMI) between 18 and 32 kg/m2
             (inclusive)

          -  Have not received any oral contraceptives during the Screening period or for at least
             15 days prior to the first dose of Period 1

        Exclusion Criteria:

          -  History of any contraindications to the combined oral contraceptive tablet including
             thrombosis and the history of any thromboembolic disease, recurrent jaundice, acute
             or chronic liver disease, hormonally-induced migraines, undiagnosed vaginal bleeding,
             significant hyperlipidemia, and mammary, endometrial, or hepatic carcinoma (known or
             suspected)

          -  Prior exposure to sotagliflozin (LX4211)

          -  History of any clinically relevant psychiatric, renal, hepatic, pancreatic,
             endocrine, cardiovascular, neurological, hematological, or GI abnormality

          -  Concurrent conditions that could interfere with safety and/or tolerability
             measurements

          -  Women who are breastfeeding or are planning to become pregnant during the study

          -  Positive serum pregnancy test

          -  Have taken injectable contraceptives or hormonal intrauterine devices within 12
             months prior to the first dose of Period 1 or topical controlled delivery
             contraceptives (patch) for 3 months prior to the first dose of Period 1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 29, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Norgestimate</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
